Aurinia Pharmaceuticals AUPH Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $80.21M-3.9% | $83.43M+70.7% | $48.88M-48.1% | $94.17M-59.4% | ||
| $41.45M+13.4% | $36.54M+51.7% | $24.09M+78.7% | $13.48M-12.5% | ||
| $183.18M+17.0% | $156.56M+13.9% | $137.43M+34.5% | $102.2M+42.1% | ||
| $491.97M+10.2% | $446.6M+5.1% | $424.8M-4.0% | $442.54M-13.8% | ||
| $2.11M-22.7% | $2.73M-18.6% | $3.35M-8.1% | $3.65M-17.4% | ||
| $3.76M-13.6% | $4.36M-12.5% | $4.98M-22.5% | $6.43M-23.5% | ||
| $751.59M+36.5% | $550.65M+0.5% | $548.06M+16.4% | $470.86M-13.3% | ||
| $3.31M-36.1% | $5.19M+19.9% | $4.33M+40.2% | $3.09M-20.4% | ||
| $3.72M-66.2% | $11M+129% | $4.81M+52.9% | $3.15M+1,557% | ||
| $16.52M+17.6% | $14.05M-3.9% | $14.61M— | $0— | ||
| $93.72M-4.1% | $97.76M+26.7% | $77.19M+67.4% | $46.11M+13.4% | ||
| $170.26M-1.7% | $173.17M+1.8% | $170.11M+160% | $65.43M+1.8% | ||
| $1.12B-5.7% | $1.19B-1.0% | $1.2B+1.3% | $1.19B+0.7% | ||
| -$649.37M+30.7% | -$936.57M+0.6% | -$942.32M-9.0% | -$864.3M-14.3% | ||
| $581.33M+54.0% | $377.48M-0.1% | $377.95M-6.8% | $405.44M-15.4% | ||
| $751.59M+36.5% | $550.65M+0.5% | $548.06M+16.4% | $470.86M-13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Aurinia Pharmaceuticals cover its short-term obligations?
- Its current ratio is 5.55 — current assets exceed current liabilities.
- Where does Aurinia Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.